Journal
Cancer Research Communications
Publication Date
7-1-2024
Volume
4
Issue
7
First Page
1793
Last Page
1801
Document Type
Open Access Publication
DOI
10.1158/2767-9764.CRC-24-0213
Rights and Permissions
Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun. 2024 Jul 1;4(7):1793-1801. doi: 10.1158/2767-9764.CRC-24-0213 This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. ©2024 The Authors; Published by the American Association for Cancer Research
Recommended Citation
Maldonado, Edward; Trikalinos, Nikolaos A; and et al., "A phase II trial of the WEE1 inhibitor adavosertib in SETD2-altered advanced solid tumor malignancies (NCI 10170)." Cancer Research Communications. 4, 7. 1793 - 1801. (2024).
https://digitalcommons.wustl.edu/oa_4/3971
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
